ZeroStack Lands $14.7M Pharma Orders, Needs Financing to Execute
ZSTK is trading near its 52-week low of $2.69 (4.5% above the low).
Summary
ZeroStack secured purchase orders for up to $14.7 million in pharmaceutical inventory from two companies, to be fulfilled through its German subsidiary Phatebo. This is a significant revenue opportunity for a company with a market cap under $7 million and only $2.3 million in cash as of last quarter. However, the company must first secure inventory financing, and there is no guarantee it will obtain it on acceptable terms. If financing falls through, the orders could be delayed or canceled. The news follows a series of highly dilutive acquisition filings and a massive Q1 loss, making this a potential lifeline if executed.
At the time of this announcement, ZSTK was trading at $2.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.9M. The 52-week trading range was $2.69 to $1,093.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: TMX Newsfile.